BALPHARMA2026-01-012026-03-31BALPHARMA2026-03-31BALPHARMA2025-03-31BALPHARMA2025-04-012026-03-31BALPHARMA2026-01-012026-03-31in-capmkt:OtherExpenses1MemberBALPHARMA2025-04-012026-03-31in-capmkt:OtherExpenses1MemberBALPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain1BALPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain2BALPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain3BALPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain4BALPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain5BALPHARMA2026-03-31OtherNoncurrentAssetsDomain1BALPHARMA2026-03-31OtherNoncurrentAssetsDomain2BALPHARMA2026-03-31OtherNoncurrentAssetsDomain3BALPHARMA2026-03-31OtherNoncurrentAssetsDomain4BALPHARMA2026-03-31OtherNoncurrentAssetsDomain5BALPHARMA2026-03-31OtherCurrentFinancialAssetsDomain1BALPHARMA2026-03-31OtherCurrentFinancialAssetsDomain2BALPHARMA2026-03-31OtherCurrentFinancialAssetsDomain3BALPHARMA2026-03-31OtherCurrentFinancialAssetsDomain4BALPHARMA2026-03-31OtherCurrentFinancialAssetsDomain5BALPHARMA2026-03-31OtherCurrentAssetsDomain1BALPHARMA2026-03-31OtherCurrentAssetsDomain2BALPHARMA2026-03-31OtherCurrentAssetsDomain3BALPHARMA2026-03-31OtherCurrentAssetsDomain4BALPHARMA2026-03-31OtherCurrentAssetsDomain5BALPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1BALPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain2BALPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain3BALPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain4BALPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain5BALPHARMA2026-03-31OtherNoncurrentLiabilitiesDomain1BALPHARMA2026-03-31OtherNoncurrentLiabilitiesDomain2BALPHARMA2026-03-31OtherNoncurrentLiabilitiesDomain3BALPHARMA2026-03-31OtherNoncurrentLiabilitiesDomain4BALPHARMA2026-03-31OtherNoncurrentLiabilitiesDomain5BALPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain1BALPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain2BALPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain3BALPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain4BALPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain5BALPHARMA2026-03-31OtherCurrentLiabilitiesDomain1BALPHARMA2026-03-31OtherCurrentLiabilitiesDomain2BALPHARMA2026-03-31OtherCurrentLiabilitiesDomain3BALPHARMA2026-03-31OtherCurrentLiabilitiesDomain4BALPHARMA2026-03-31OtherCurrentLiabilitiesDomain5BALPHARMA2026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524824BALPHARMANOTLISTEDINE083D01012BAL PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-05-272026-05-18INRLakhsQuarterlyFourth quarterSingle segmentPHARMACEUTICLES2026-05-2716:30:002026-05-2717:30:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated840757000-236500083839200041136500014203000-422960001806550004055500030580000171156000806218000321740000321740000-3862000-38620000360360000000360360004385000404210003593500010200000159209000102.262.26002.262.261. The consolidated financial results were reviewed by audit committee and approved by the Board of Directors at their meetings held on 27.05.2026. <BR> 2. The Company delals with a single segment i.e Pharmaceuticles. <BR> 3. The consoidated financial results have been prepared in accordance with Companies ( IND AS) rules ,2015 prescribed under section 133 of Companies Act,2013 read with relevant rules issued there in and recognised accounting policies and practises to the extent applicable. <BR> 4. The figures for 31st March 2026 & 2025 and balancing figures between audited figures with respect to full financial year and unaudited published year todate figures upto the 3rd quarter of the relevant financial years which were subjected to limited review by the statutory auditors. <BR> 5. The Board has recommedned a dividned of Re.1 per equity share of Rs.10 each. <BR> 6. Previous period figures have been regroupd & rearranged whereever required.2025-04-012026-03-31AuditedConsolidated3116613000192780003135891000160967400092266000-1222890006646480001681760001107930005532640003076532000593590000593590000-3862000-38620000632210000000632210004385000676060006283600036500000159209000106630650003.953.95003.953.95Other Expenses171156000Other Expenses5532640007675150007424200003826900013422400000000080709000807090008041000300620001133062000116355300020817000936327000230110001165700006549000010573020001343000400138000262233600000375539800015920900066306500082227400025000082252400031884800000059731000378579000620160000004405950001276316000392600088575800088968400024624500024122450007237000076640000024922790000029328740003755398000180709000000000001300620000000000014908900021640100000000004001380000000000015973100000000000000000000012462450000000000017237000000000000-8468000-56100006184000168176000-15338000200011079300028100000433700000000000000000000265406000324765000-133332000-19415000-332000-3281000-1351280007866900072824000196583000405500016330000000000000000000000000141630008652000000-98522000-1855490000-3825100005610007833000841300054950001751600003411800019500057243000-191050000-273221000-2930740001000-293073000-168120000-461193000-4385000-438500043850004385000AuditedtrueSSJNB & COtrue2029-03-31